Related Experiment Video
Updated: Jul 11, 2025
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
Intracranial Germ Cell Tumors
Teri Danielle You Ying Yeoh1, Vincent Nga2, Miriam Kimpo3
1Department of Radiation Oncology, National University Cancer Institute Singapore, National University Hospital, Singapore.
Abstract:
Intracranial germ cell tumors are rare tumors occurring in adolescents and young adults, which include germinomas and non-germinomatous type germ cell tumors (NGGCT). In the past few decades, cooperative trial groups in Europe and North America have developed successful strategies to improve survival outcomes and decrease treatment-related toxicities. New approaches to establishing diagnosis have deferred the need for radical surgery. The 5-year event-free survival (EFS) is above 90% and even patients who present with metastatic germinoma can still be cured with chemotherapy and craniospinal irradiation. The combination of surgery, chemotherapy, and radiation therapy is tailored to patients based on grouping and staging. For NGGCT, neoadjuvant chemotherapy followed by delayed surgery for residual disease and radiotherapy can yield a 5-year EFS of 70%. Further strategies should focus on reducing long-term complications while preserving high cure rates.
Insights
Intracranial germ cell tumors in young adults show high survival rates with modern treatments. Advances in diagnosis and therapy improve outcomes while reducing toxicity for these rare cancers.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Rare Cancers
Background:
- Intracranial germ cell tumors (IGCTs) are rare, affecting adolescents and young adults.
- IGCTs include germinomas and non-germinomatous germ cell tumors (NGGCTs).
- Recent decades saw improved survival and reduced toxicity through cooperative group trials.
Purpose of the Study:
- To review current strategies for treating IGCTs.
- To highlight advancements in diagnosis and therapy.
- To discuss survival outcomes and future directions.
Main Methods:
- Review of cooperative trial group data from Europe and North America.
- Analysis of treatment strategies including surgery, chemotherapy, and radiation therapy.
- Evaluation of diagnostic advancements reducing the need for radical surgery.
Main Results:
- 5-year event-free survival (EFS) exceeds 90% for germinomas, even with metastatic disease.
- Combined modality treatment (surgery, chemotherapy, radiotherapy) is tailored by staging.
- For NGGCTs, neoadjuvant chemotherapy followed by surgery and radiotherapy yields a 5-year EFS of 70%.
Conclusions:
- Current treatment strategies significantly improve survival for IGCTs.
- Focus is shifting towards minimizing long-term treatment complications.
- Preserving high cure rates remains paramount in IGCT management.
